Therapeutic Effects of Sparsentine

On February 17, 2023, Sparsentan received accelerated approval in the United States for the reduction of proteinuria in adult patients with primary IgA nephropathy who are at risk for rapid disease progression and typically have a urine protein to creatinine ratio (UP/C) ≥ 1.5 g/g. It is the first and currently only approved non-immunosuppressive therapy for the treatment of IgA nephropathy.

This indication is approved under accelerated approval based on proteinuria reduction. It has not been established whether spaxantane slows the decline in kidney function in patients with IgAN. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory clinical trials.

This accelerated approval is based on clinically meaningful and statistically significant improvement in proteinuria compared with the active comparator in the pivotal and ongoing Phase 3 PROTECT study, the largest head-to-head interventional study of sparsentan to date. The PROTECT study was a global, randomized, multicenter, double-blind, active-controlled clinical trial evaluating the safety and efficacy of sparsentan 400 mg versus irbesartan 300 mg in 404 patients 18 years and older with persistent IgAN. Proteinuria occurs despite maximal tolerated ACE or ARB therapy.

Topline interim results are based on the prespecified primary analysis set, which showed that after 36 weeks of treatment, proteinuria decreased by an average of 49.8% from baseline in patients treated with sparsentan, while proteinuria decreased by an average of 15.1% from baseline in patients treated with irbesartan. As required by the FDA, the efficacy data included in the US FDA-approved labeling were a post hoc sensitivity analysis evaluating the first 281 randomized patients (a subset of the entire trial population). In a post hoc sensitivity analysis, the mean reduction in proteinuria from baseline was 45% for sparsentan and 15% for the active control irbesartan. Both prespecified and post hoc sensitivity analyzes demonstrated that sparsentan achieved rapid and sustained reductions in proteinuria, with statistically significant and clinically meaningful improvements compared with the active comparator irbesartan.

Overall, Sparsentine is healingIt has shown significant therapeutic effects in IgA nephropathy, especially in reducing proteinuria and protecting kidney function. However, patients still need to pay close attention to the body's reaction when using it and seek medical advice promptly if any discomfort occurs. The above information is mainly based on clinical trials and research data, and actual results may vary due to individual differences. Therefore, patients should consult their physician for professional advice before using sparsentane.